Steady-State Pharmacokinetics of a New 4-Gram 5-Aminosalicylic Acid Retention Enema in Patients with Ulcerative Colitis in Remission

References

• Azad Khan A K, Piris J, Truelove S C. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977; 2: 892–895
   PubMed Web of Science ®Google Scholar
• van Hees P A M, Bakker J H, van Tongeren J H M. Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine. Gut 1980; 21: 632–635
   PubMed Web of Science ®Google Scholar
• Klotz U, Maier K, Fischer C, Heinkel K. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. N Engl J Med 1980; 303: 1499–1502
   PubMed Web of Science ®Google Scholar
• Schroeder H, Campbell D E S. Absorption, metabolism and excretion of salicylazosulfapyridine in man. Clin Pharmacol Ther 1972; 13: 539–551
   PubMed Web of Science ®Google Scholar
• Nielsen O H, Bondesen S. Kinetics of 5-aminosalicylic acid after jejunal installation in man. Br J Clin Pharmacol 1983; 16: 738–740
   PubMed Web of Science ®Google Scholar
• Myers B, Evans D N W, Rhodes J, et al. Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut 1987; 28: 196–200
   PubMed Web of Science ®Google Scholar
• Järnerot G. Newer 5-aminosalicylic acid based drugs in chronic inflammatory bowel disease. Drugs 1989; 37: 73–86
   PubMed Web of Science ®Google Scholar
• Williams C N, Haber G, Aquino J A. Double-blind, placebo-controlled, evaluation of 5-ASA suppositories in active distal proctitis and measurement of extent of spread using 99m-Tc-labeled 5-ASA suppositories. Dig Dis Sci 1987; 32: S71–S75, suppl
   PubMed Web of Science ®Google Scholar
• Borgen L A, Hanauer S, Good L, Williams C N, Haber G. Mesalamine suppository efficacy in ulcerative proctitis: a multicenter placebo-controlled trial. Gastroenterology 1988; 94: 42
   Web of Science ®Google Scholar
• Campieri M, Lanfranchi G A, Bazzocchi G, et al. Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas. Lancet 1981; 2: 270–271
   PubMed Web of Science ®Google Scholar
• Willoughby C P, Campieri M, Lanfranchi G, Truelove S C, Jewell D P. 5-Amino-salicylic acid (Pentasa) in enema form for the treatment of active ulcerative colitis. Ital J Gastroenterol 1986; 18: 15–17
   Google Scholar
• Sutherland L R, Martin F, Greer S, et al. 5-Amino-salicyclic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987; 92: 1894–1898
   PubMed Web of Science ®Google Scholar
• Danish 5-ASA group. Topical 5-aminosalicylic acid versus prednisolone in ulcerative proctosigmoiditis. A randomized, double-blind multicenter trial. Dig Dis Sci 1987; 32: 598–602
   PubMed Web of Science ®Google Scholar
• Janssens J, Geboes K, Delanote C, Vantrappen G. 5-Aminosalicylic acid (5-ASA) enemas are effective in patients with resistent ulcerative rectosigmoiditis. Gastroenterology 1983; 84: 1198
   Web of Science ®Google Scholar
• Barber G B, Lee D E, Antonioli D A, Peppercorn M A. Refractory distal ulcerative colitis responsive to 5-aminosalicylate enemas. Am J Gastroenterol 1985; 80: 612–614
   PubMed Web of Science ®Google Scholar
• Friedman L S, Richter J M, Kirkham S E, DeMonaco H J, May R J. 5-Amino-salicylic acid enemas in refractory distal ulcerative colitis: a randomized, controlled trial. Am J Gastroenterol 1986; 81: 412–418
   PubMed Web of Science ®Google Scholar
• Hanauer S B, Schultz P A. Efficacy of 5-ASA enemas for steroid dependent ulcerative colitis. Gastroenterology 1986; 90: 1449
   Web of Science ®Google Scholar
• Guarino J, Chatzinoff M, Berk T, Friedman L S. 5-Aminosalicylic acid enemas in refractory distal ulcerative colitis: long-term results. Am J Gastroenterol 1987; 82: 732–737
   PubMed Web of Science ®Google Scholar
• McPhee M S, Swan J T, Biddle W L, Greenberger N J. Proctocolitis unresponsive to conventional therapy. Response to 5-aminosalicylic acid enemas. Dig Dis Sci 1987; 32: S76–S81, suppl
   PubMed Web of Science ®Google Scholar
• Hanauer S B, Shultz P A. Relapse rates after successful treatment of refractory colitis with 5-ASA enemas. Gastroenterology 1987; 92: 1424
   Web of Science ®Google Scholar
• Norlander B, Gotthard R, Strom M. Pharmacokinetics of a 5-aminosalicylic acid enteric-coated tablet and suppository dosage form. Aliment Pharmacol Ther 1989; 3: 333–342
   PubMed Web of Science ®Google Scholar
• Dew M J, Cardwell M, Kidwai N S, Evans B K, Rhodes J. 5-Aminosalicylic acid in serum and urine after administration by enema to patients with colitis. J Pharm Pharmacol 1983; 35: 323–324
   PubMed Web of Science ®Google Scholar
• Bondesen S, Nielsen O H, Jacobsen O, et al. 5-aminosalicylic acid enemas in patients with active ulcerative colitis. Influence of acidity on the kinetic pattern. Scand J Gastroenterol 1984; 19: 677–682
   PubMed Web of Science ®Google Scholar
• Campieri M, Lanfranchi G A, Boschi S, et al. Topical administration of 5-aminosalicylic acid enemas in patients with ulcerative colitis. Studies on rectal absorption and excretion. Gut 1985; 26: 400–405
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Belluzzi A, Campieri M, et al. 5-aminosalicylic acid in patients with ulcerative colitis in remission: plasma levels after administration of a new rectal enema. Methods Find Exp Clin Pharmacol 1988; 10: 667–669
   PubMedGoogle Scholar
• Fischer C, Maier K, Stumpf E, von Gaisberg U, Klotz U. Disposition of 5-aminosalicylic acid, the active metabolite of sulphasalazine, in man. Eur J Clin Pharmacol 1983; 25: 511–515
   PubMed Web of Science ®Google Scholar
• Bondesen S, Nielsen O H, Schou J B, et al. Steady-state kinetics of 5-aminosalicylic acid and sulfa-pyridine during sulfasalazine prophylaxis in ulcerative colitis. Scand J Gastroenterol 1986; 21: 693–700
   PubMed Web of Science ®Google Scholar
• Lauritsen K, Laursen L S, Bukhave K, Rask-Madsen J. Longterm olsalazine treatment: pharmacokinetics, tolerance and effects on local eicosanoid formation in ulcerative colitis and Crohn's colitis. Gut 1988; 29: 974–982
   PubMed Web of Science ®Google Scholar
• Calder I C, Funder C C, Green C R, Ham K N, Tange J D. Nephrotoxic lesions from 5-aminosalicylic acid. Br Med J 1972; 1: 152–154
   PubMed Web of Science ®Google Scholar
• Briggs D, Calder I, Woods R, Tange J. The influence of metabolic variation on analgesic nephrotoxicity. Experiments with the Gunn rat. Pathology 1982; 14: 349–353
   PubMed Web of Science ®Google Scholar
• Tremaine W J, Schroeder K W. Oral 5-aminosalicylic acid (Asacol) tolerance versus oral sulfasalazine tolerance in patients with chronic ulcerative colitis. Gastroenterology 1986; 90: 1670
   Web of Science ®Google Scholar
• Tremaine W J, Schroeder K W. Urinary sediment abnormalities in patients on long-term oral 5-aminosalicylic acid (5-ASA) for chronic ulcerative colitis. Gastroenterology 1988; 94: 465
   Web of Science ®Google Scholar
• Novis B H, Korzets K, Chen P, Bernheim J. Nephrotic syndrome after treatment with 5-aminosalicylic acid. Br Med J 1988; 296: 1442
   PubMed Web of Science ®Google Scholar
• Riley S A, Mani V, Goodman M J, Herd M E, Dutt S, Turnberg L A. Comparison of delayed release 5-aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. Gut 1988; 29: 669–674
   PubMed Web of Science ®Google Scholar
• Diener U, Tuczek H V, Fische C, Maier K, Klotz U. Renal function was not impaired by treatment with 5-aminosalicylic acid in rats and man. Naunyn-Schmiedebergs Arch Pharmacol 1984; 326: 278–282
   PubMed Web of Science ®Google Scholar
• Ireland A, Priddle J D, Jewell D P. Studies on the acetylating capacity of human colonic epithelial cells for 5-aminosalicylic acid. Scand J Gastroenterol 1988; 23(suppl 148)53
   PubMedGoogle Scholar
• van Hogezand R A. 5-aminosalicylic acid compounds, pharmacokinetics and clinical aspects. Thesis, Krips Repro Meppel, The Netherlands 1986
   Google Scholar
• Allgayer H, Kruis W, Paumgartner G. Different acetylation of 5-aminosalicylic acid (5-ASA) in mucosa and feces. In: Clinical controversies in inflammatory bowel disease. Abstract book. Tipografia Negri S.R.L., Bologna 1987; 159
   Google Scholar
• Dull B J, Salata K, Goldman P. Role of the intestinal flora in the acetylation of sulfasalazine metabolites. Biochem Pharm 1987; 36: 3772–3774
   PubMed Web of Science ®Google Scholar
• Willoughby C P, Piris J, Truelove S C. The effect of topical N-acetyl-5-aminosalicylic acid in ulcerative colitis. Scand J Gastroenterol 1980; 15: 715–719
   PubMed Web of Science ®Google Scholar
• Binder V, Halskov S, Hvidberg E, et al. A controlled study of 5-acetaminosalicylic acid as enema in ulcerative colitis. Scand J Gastroenterol 1981; 16: 1122A
   Web of Science ®Google Scholar
• Bondesen S, Hegnhöj J, Hansen S H, Larsen F, Hansen C P, Rasmussen S N. The fate of systemic 5-aminosalicylic acid (5-ASA) in man. Scand J Gastroenterol 1989; 24(suppl 159)63
   Google Scholar
• Borgen L A, Patel V, Powell D. Relative systemic absorption of 5-aminosalicyclic acid rectal dosage forms. Gastroenterology 1986; 90: 1714
   Web of Science ®Google Scholar
• Pieniaszek H J, Bates T R. Capacity-limited gut wall metabolism of 5-aminosalicylic acid, a therapeutically active metabolite of sulfasalazine, in rats. J Pharmaceut Sci 1979; 68: 1323–1325
   PubMed Web of Science ®Google Scholar
• Campieri M, Lanfranchi G A, Brignola C, et al. Retrograde spread of 5-aminosalicylic acid enema in patients with active ulcerative colitis. Dis Colon Rectum 1986; 29: 108–110
   PubMed Web of Science ®Google Scholar
• Bechgaard E. Absorption of salicylic acid from the perfused human rectum. Acta Pharmacol Toxicol 1973; 33: 129–137
   PubMedGoogle Scholar
• de Boer A G, Moolenaar F, de Leede L G J, Breimer D D. Rectal drug administration: clinical pharmacokinetic considerations. Clin Pharmacokin 1982; 7: 285–311
   PubMed Web of Science ®Google Scholar
• Fallingborg J, Christensen L A, Ingeman-Nielsen M, et al. pH-profile of the normal gut measured by a radiotelemetry device. Scand J Gastroenterol 1989; 24(suppl 159)99
   Google Scholar
• Bondesen S, Schou J F, Pedersen V, Rafiolsadat Z, Hansen S H, Hvidberg E F. Absorption of 5-aminosalicylic acid from colon and rectum. Br J Clin Pharmacol 1988; 25: 269–272
   PubMed Web of Science ®Google Scholar
• Dull B J, Salata K, van Langenhove A, Goldman P. 5-aminosalicylate: oxidation by activated leukocytes and protection of cultured cells from oxidative damage. Biochem Pharmacol 1987; 36: 2467–2472
   PubMed Web of Science ®Google Scholar
• Ahnfelt-Rønne I, Nielsen O H, Christensen A, Langholz E, Binder V, Riis P. Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid. Gastroenterology 1990; 98: 1162–1169
   PubMed Web of Science ®Google Scholar